ENVB
NASDAQ · Pharmaceuticals
Enveric Biosciences Inc
$1.58
+0.02 (+1.28%)
Financial Highlights (FY 2026)
Revenue
16.93B
Net Income
-111,187,917
Gross Margin
20.4%
Profit Margin
-14.0%
Rev Growth
+3.4%
D/E Ratio
—
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | 20.4% | 20.4% | 41.7% | 41.7% |
| Operating Margin | -15.8% | -14.3% | 22.8% | 23.8% |
| Profit Margin | -14.0% | -13.3% | 23.5% | 24.3% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 16.93B | 16.38B | 1.01M | 1.10M |
| Gross Profit | 3.46B | 3.35B | 420.4K | 458.4K |
| Operating Income | -2,682,123,985 | -2,335,666,750 | 229.8K | 261.8K |
| Net Income | -111,187,917 | -96,825,471 | 237.2K | 267.5K |
| Gross Margin | 20.4% | 20.4% | 41.7% | 41.7% |
| Operating Margin | -15.8% | -14.3% | 22.8% | 23.8% |
| Profit Margin | -14.0% | -13.3% | 23.5% | 24.3% |
| Rev Growth | +3.4% | +3.4% | -4.2% | +11.1% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 0 | 0 | 697.3K | 671.8K |
| Total Equity | — | — | 1.18M | 1.26M |
| D/E Ratio | — | — | 0.59 | 0.53 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | -108,673,271 | -99,893,185 | 375.3K | 375.0K |
| Free Cash Flow | — | — | 127.9K | 141.2K |